- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Not listed
- Lead sponsor
- Unity Health Toronto
- Other
- Eligibility
- Not listed
- Enrollment
- 2,272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–30
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epistaxis
- Interventions
- Doxycycline, Placebo
- Drug · Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- VAD044 Part I, VAD044 Part II
- Drug
- Lead sponsor
- Vaderis Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
- Interventions
- Pomalidomide
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- Hanny Al-Samkari, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Interventions
- Submucosal Bevacizumab
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- San Diego, California